Skip to main content

Table 1 Overview of data sources characteristics (n = 53)

From: Inventory of real world data sources in Parkinson’s disease

Characteristics

Included

Status

Country

Study population

All (n = 53)

Ongoing (n = 16)

Completed (n = 37)

USA (n = 42)

International (n = 11)

Parkinson cohort

(n = 25)

“Generic” cohort

(n = 28)

Size (number of Parkinsonian patients)

 

0-500

42 (79)

11 (69)

31 (84)

37 (88)

5 (45)

22 (88)

20 (71)

500-1000

7 (13)

4 (25)

3 (8)

3 (7)

4 (36)

3 (12)

4 (14)

>1000

4 (8)

1 (6)

3 (8)

2 (5)

2 (18)

0 (0)

4 (14)

Duration of follow-up (years)

 

<2

6 (11)

0 (0)

6 (16)

4 (10)

2 (18)

4 (16)

2 (7)

2-5

20 (38)

4 (25)

16 (43)

16 (38)

4 (36)

13 (52)

7 (25)

≥5

27 (51)

12 (75)

15 (41)

22 (52)

5 (45)

8 (32)

19 (68)

Dimensions assessed

 

Motor and neurological

46 (87)

12 (75)

34 (92)

36 (86)

10 (91)

25 (100)

21 (75)

Cognition

41 (77)

13 (81)

28 (76)

36 (86)

5 (45)

17 (68)

24 (86)

Psychiatric symptoms

38 (72)

10 (63)

28 (76)

30 (71)

8 (73)

19 (76)

17 (61)

Activities of daily living

22 (42)

6 (38)

16 (43)

15 (36)

7 (64)

12 (48)

10 (36)

Sleep quality

11 (21)

4 (25)

7 (19)

5 (12)

6 (55)

2 (8)

9 (32)

Quality of life

9 (17)

4 (25)

5 (14)

5 (12)

4 (36)

6 (24)

3 (11)

Autonomic symptoms

7 (13)

4 (25)

3 (8)

3 (7)

4 (36)

0 (0)

7 (25)

Other

20 (38)

9 (56)

11 (30)

13 (31)

7 (64)

8 (32)

12 (43)

Other assessments

 

Current medications

43 (81)

13 (81)

30 (81)

32 (76)

11 (100)

22 (88)

21 (75)

Comorbidities

42 (79)

14 (88)

28 (76)

31 (74)

11 (100)

20 (80)

22 (79)

Medical imaging

19 (36)

6 (40)

13 (34)

11 (26)

8 (73)

6 (24)

13 (46)

Genetics

16 (30)

6 (38)

10 (27)

10 (24)

6 (55)

3 (12)

13 (46)

Caregiver burden

6 (11)

4 (27)

2 (5)

5 (12)

1 (9)

4 (16)

2 (7)

Healthcare costs

1 (2)

1 (7)

0 (0)

0 (0)

1 (9)

1 (4)

0 (0)

  1. Data are shown as absolute frequency (percentage)